Ra Medical Systems, Inc. (RMED) gained in the pre-market after announcing its 10th patent. RMED values at $0.42, gaining more than 4% compared to yesterday’s closing price. The stock closed at $0.40 at the end of the last trading session. The stock volume traded in the last trading session was around 2.22 million shares. The current market cap of the company is around $6.66 million.

Ra Medical Systems, Inc. (RMED) announced its 10th U.S. patent

It was on February 8, 2022, when a new patent for an arterial plaque blockage laser ablation support catheter was issued to RMED. With its tenth U.S. patent, Ra Medical has created innovative liquid core ablation catheters.

Laser Ablation in Body Lumens and Methods of Use with a Small Flexible Liquid Core Catheter is described in detail in the article. The DABRA ablation and support catheters have been tested in difficult-to-treat peripheral veins by medical experts at RMED.

RMED CEO’s remarks on the patent

Our DABRA liquid core ablation catheters can now be used in difficult anatomies, according to CEO Will McGuire. He also said that we are certain that this patent will speed up the commercialization of the DABRA excimer laser system.

RMED lost more than 94% in the Trailing Twelve Months

Ra Medical Systems, Inc. (RMED) lost more than 94% value in twelve months. The company is struggling to make significant revenue. Five years ago, the stock’s value was $455 per share, but it sells for peanuts at $0.42, losing more than 99% value. The revenue in the last reported quarter was a mere $5K.

Conclusion

Ra Medical Systems, Inc. (RMED) is not profitable for the past few years and is barely making any money. The new patent might seem like a savior, but the company needs to focus on rolling the treatment.